{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002378","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.835515+00:00","generated_at":"2026-05-18T06:47:14.523239+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion shareholders approve 1-for-15 reverse split and board election","bullets":["Reverse share split at 1-for-15 ratio approved with 59.6% of votes in favor.","Equity incentive plan shares increased by 1,271,859 to 1,428,268 total.","All seven director nominees elected; Ruth Alon (68.2%) and Ilan Levin (68.1%) received lowest support.","Ratification of Kesselman & Kesselman (PwC) as auditors approved with 98.3% in favor.","Meeting reconvened after July 7 adjournment due to lack of quorum; 12.1% of shares represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002378","json":"https://secwatch.observer/filing/0001178913-25-002378.json","markdown":"https://secwatch.observer/filing/0001178913-25-002378.md","text":"https://secwatch.observer/filing/0001178913-25-002378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002378/0001178913-25-002378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002378/zk2533438.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:47:14.523239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}